Latest Regulatory News

Alterity Therapeutics has reported encouraging topline results from its open-label Phase 2 trial of ATH434 in advanced Multiple System Atrophy, showing slowed disease progression and biomarker stabilization.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Larvotto Resources has opened a $5 million Share Purchase Plan offering shares at a 13.5% discount to fund key development and exploration activities at its Hillgrove Project in NSW.

Anax Metals has raised $3.3 million through convertible notes to push forward its Whim Creek copper-zinc project in Western Australia, while resolving a recent arbitration with its cornerstone investor Mineral Development Partners.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

Morris Group has launched a conditional, non-binding takeover proposal for Reef Casino Trust, offering $3.70 per unit, rivaling the existing Iris bid. The Independent Board Committee urges unitholders to hold off while assessing this alternative.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.

UNITH Ltd reported a record quarterly cash receipt of $1.6 million in Q4 FY25, driven by strategic partnerships and platform innovations. The company is poised for growth with a new website launch and expanded European presence.

Latrobe Magnesium Limited has extended its Pilot Project Licence with EPA Victoria until February 2027, paving the way to resume magnesium oxide production at its Hazelwood North site in August 2025.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.